Sharescart Research Club logo
Products
Research
Tools
About
ChatGPT Claude Perplexity
Summarize with
ChatGPT Claude Perplexity
Join Channel
Apollo Green₹ 72 (28.6%)ASK Investment₹ 895 (-3.2%)AVPL ₹ 49 (0%)Bootes Impex₹ 775 (-8.8%)CIAL ₹ 442 (-0.5%)CSK ₹ 254 (-3.1%)ESDS Software₹ 478 (2.8%)Garuda Aerospace₹ 468 (-2.1%)Goodluck Defence₹ 385 (16%)Hero Motors₹ 325 (0%)Hinduja Leyland₹ 248 (0%)ICL Fincorp₹ 25 (0%)Incred Holdings₹ 154 (2.7%)Kineco Limited₹ 3285 (0%)Lava ₹ 60 (15.4%)Market Simplified₹ 26 (-7.1%)Matrix Gas₹ 12 (-20%)Motilal Oswal₹ 12.25 (-2%)MSEI ₹ 6.35 (-2.3%)NCDEX ₹ 368 (-1.6%)NSE ₹ 1985 (-2%)Onix Renewable₹ 68 (21.4%)OYO ₹ 23 (-4.2%)OYO Assets₹ 9.25 (-7%)Philips India₹ 1250 (0%)Polymatech Electronics₹ 56 (-3.4%)SBI Mutual₹ 768 (-0.9%)Taparia Tools₹ 6050 (0%)VCI Chemical₹ 64 (0%)Zepto ₹ 40 (-4.8%)

15 Days Price Change

Suraksha Diagnostic IPO

Closing In

  • days
  • Hours
  • Minutes
  • Seconds
Profile
Issue Size --
Profile
Price Range 420  to  441 per share
Profile
Min Investment ₹441
Profile
Lot Size 1
Profile
Face Value ₹2
Profile
Draft Prospectus --
Invest Before the IPO Goes Live

Buy unlisted shares early and participate in the growth before public listing.

Profile
  • Basic Info
  • IPO Tentative Timetable
  • IPO Lot Size
  • Subscription Status
  • Financials
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • Ratios
  • Growth Rates
  • Other info

Overview

Suraksha Diagnostic Limited, established in 2005, provides a range of medical services including pathology, radiology testing, and medical consultancy. The company operates a central reference laboratory along with eight satellite laboratories and 215 customer touchpoints, which include 49 diagnostic centers and 166 sample collection centers across West Bengal, Bihar, Assam, and Meghalaya as of June 30, 2024. Suraksha offers both online and offline medical consultations at its 44 diagnostic centers, which house 120 polyclinics staffed by over 750 doctors. Its operations are supported by advanced technology platforms such as the Laboratory Information Management System (LIMS), Radiology Information System (RIS), Picture Archive Communication System (PACS), and Enterprise Resource Planning (ERP) systems. Additionally, the company provides vaccination services and tailored testing packages for disease prediction and early detection. Utilizing digital pathology and artificial intelligence, Suraksha enhances its blood testing processes, while all radiology reports are generated digitally to reduce turnaround times. Suraksha’s competitive strengths include its strategic positioning in eastern and northeastern India’s fragmented diagnostic market, offering integrated services, advanced clinical infrastructure, a commitment to quality, and a highly experienced management team. Read More

Basic Info

Face Value 2 per share

Price 420  to  441 per share

P/E (x) 73.5

Sales( Cr.) 252

PAT( Cr.) 31

EPS 6

Draft Prospectus --

Exchange BSE-NSE

Promoter

Company Promoters

Dr. Somnath Chatterjee Ritu Mittal Satish Kumar Verma.

Pre Issue Share Holding 100%

Post Issue Share Holding 64.29%

Listing Details:

Listing Price: 437

Listing Gain: -0.92%

Current Price: 285.8

Gain On Issue: 285.8 | 0%

GMP: --

GMP %: -- %

IPO Tentative Timetable

Opening Date Nov 29, 2024
Closing Date Dec 03, 2024
Allotment Dec 04, 2024
Refund Dec 05, 2024
Delivery of Shares Dec 05, 2024
Listing Date Dec 06, 2024

IPO Lot Size

Application Lots Shares Amount
Retail (Min) 1 34 14,994
Retail (Max) 13 442 194,922
S-HNI (Min) 14 476 209,916
S-HNI (Max) 66 2244 989,604
B-HNI (Min) 67 2278 1,004,598

Objective of the Issue

1. The Company will not receive any proceeds from the Offer for sale and all proceeds will go to the Selling Shareholders

Issue

Category Nos Bid Bid (x)
QIB 9594665 16694717 1.7x
NII 2878400 4029760 1.4x
Retail 6716266 6313290 0.9x
EMP 0 0 0x
Total 19189330 24370449 1.3x

Net Sales (in cr.)

Total Income (in cr.)

Operating Profit (in cr.)

Net Profit (in cr.)

Shareholder Funds (in cr.)

Total Assets (in cr.)

Suraksha Diagnostic Profit & Loss

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 70 99 157 140 223 190 219 252
Other Income 1 1 2 1 2 4 4 4
Total Income 71 100 159 141 225 194 222 256
Total Expenditure 53 77 123 117 175 146 148 170
Operating Profit 19 23 36 24 50 48 74 86
Interest 1 4 2 2 2 10 10 9
Depreciation 6 9 13 16 15 32 33 35
Exceptional Income / Expenses -0 0 0 0 0 0 -1 0
Profit Before Tax 12 10 21 6 33 7 31 41
Provision for Tax 4 5 6 -0 9 1 8 10
Profit After Tax 8 5 15 6 24 6 23 31
Adjustments 0 0 0 0 0 0 0 1
Profit After Adjustments 8 5 15 6 24 7 24 32
Adjusted Earnings Per Share 109.6 79.7 220.5 93.3 344.2 94.4 342.4 6.1

Suraksha Diagnostic Balance Sheet

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds 49 55 120 126 150 156 179 211
Minority's Interest 0 0 0 0 0 -0 -0 -1
Borrowings 19 29 8 10 12 8 5 3
Other Non-Current Liabilities 6 9 11 10 10 79 76 78
Total Current Liabilities 30 33 34 25 28 38 39 43
Total Liabilities 104 125 173 171 201 281 300 334
Fixed Assets 73 91 128 119 119 195 212 223
Other Non-Current Assets 6 8 17 25 60 18 16 63
Total Current Assets 25 26 28 27 22 68 72 47
Total Assets 104 125 173 171 201 281 300 334

Suraksha Diagnostic Cash Flow

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 18 12 3 4 3 3 2 3
Cash Flow from Operating Activities 20 13 31 24 42 44 60 63
Cash Flow from Investing Activities -42 -26 -20 -28 -44 -21 -35 -40
Cash Flow from Financing Activities 17 10 -10 3 1 -24 -25 -24
Net Cash Inflow / Outflow -6 -3 1 -1 -0 -1 0 -0
Closing Cash & Cash Equivalent 12 9 4 3 3 2 3 2

Suraksha Diagnostic Ratios

# Mar 2015 Mar 2016 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) 109.61 79.69 220.48 93.26 344.2 94.43 342.4 6.11
CEPS(Rs) 190.66 212.72 403.02 320.97 562.91 546.9 807.6 12.73
DPS(Rs) 0 0 0 0 0 0 0 0
Book NAV/Share(Rs) 695.52 775.22 1712.46 1805.72 2149.92 2236.19 2576.52 40.52
Core EBITDA Margin(%) 24.8 22.24 21.65 16.15 21.54 23.37 32.41 32.5
EBIT Margin(%) 18.59 14.2 14.63 5.91 15.81 8.58 18.77 20.02
Pre Tax Margin(%) 16.49 10.1 13.34 4.55 14.87 3.55 14.38 16.42
PAT Margin (%) 10.77 5.55 9.66 4.6 10.64 3.19 10.57 12.29
Cash Profit Margin (%) 18.74 14.81 17.66 15.82 17.4 19.85 25.48 26.29
ROA(%) 7.3 4.8 10.2 3.74 12.78 2.52 7.96 9.78
ROE(%) 15.76 10.84 17.73 5.3 17.4 4.01 13.93 15.93
ROCE(%) 16.8 16.12 20.19 6.04 22.65 9.62 22.94 24.92
Receivable days 13.93 13.32 12.22 15.63 11.09 11.76 11.31 16.42
Inventory Days 11.09 11.08 10.81 12.89 8.72 11.89 10.71 10.66
Payable days 487.36 290.78 196.29 181.56 80.01 185.93 190.4 173.33
PER(x) 0 0 0 0 0 0 0 42.19
Price/Book(x) 0 0 0 0 0 0 0 6.36
Dividend Yield(%) 0 0 0 0 0 0 0 0
EV/Net Sales(x) 0.34 0.41 0.1 0.15 0.11 -0.17 -0.17 5.27
EV/Core EBITDA(x) 1.3 1.76 0.45 0.86 0.49 -0.68 -0.51 15.49
Net Sales Growth(%) 0 41.2 58.87 -11.11 59.42 -14.81 15.03 15.26
EBIT Growth(%) 0 7.84 63.76 -64.09 326.43 -53.8 151.76 22.95
PAT Growth(%) 0 -27.3 176.66 -57.7 269.06 -74.46 281.31 33.95
EPS Growth(%) 0 -27.3 176.66 -57.7 269.06 -72.56 262.58 -98.22
Debt/Equity(x) 0.58 0.77 0.1 0.13 0.13 0.09 0.05 0.03
Current Ratio(x) 0.84 0.8 0.83 1.1 0.78 1.77 1.84 1.1
Quick Ratio(x) 0.76 0.68 0.67 0.92 0.55 1.61 1.67 0.92
Interest Cover(x) 8.87 3.46 11.33 4.35 16.78 1.71 4.27 5.56
Total Debt/Mcap(x) 0 0 0 0 0 0 0 0

Sihora Industries Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 15% 4% 10% 0%
Operating Profit CAGR 16% 20% 19% 0%
PAT CAGR 35% 9% 16% 0%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR -13% NA% NA% NA%
ROE Average 16% 11% 11% 13%
ROCE Average 25% 19% 17% 17%

Company Contact Information

Suraksha Diagnostic Ltd.

Plot No D G-12/1, Action Area 1 D Premises No 02-0327, New Town Rajarhat

IPO Lead Manager(s)

Suraksha Diagnostic Ltd.

ICICI Securities Ltd

Nuvama Wealth Management Ltd.

SBI Capital Markets Ltd

Registrar Info

Suraksha Diagnostic Ltd.

Frequently Asked Questions

All You Need To Know About IPO

When you leave without vesting, generally unvested ESOPs are cancelled. Vested ESOPs usually can be exercised after you depart, often within 3 to 6 months, depending on the company's ESOP plan.

For companies listed on a stock exchange, you can sell the shares any time after you exercise the ESOP option and the shares are in your demat account. If the company is unlisted or otherwise a startup, you can only sell the shares if and when the company announces a buyback or has a process for secondary sales.

Whenever you exercised your options to hold shares, you entered into a market risk situation, and if the valuation of the company drops, so do the shares.

Yes. ESOPs are valuable to the employer in that the employer is able to retain the best talent, align employee interests with company goals, and preserve cash while rewarding performance.

Wealth Icon
Don’t Miss Out on Unlisted Shares

Open your account today and gain instant access to top unlisted shares and pre-IPO opportunities.

whatsapp

Error!